Axoltis Pharma

02/02/2026 | Press release | Archived content

NX210c Demonstrates Therapeutic Potential to Restore Blood–Brain Barrier in a QSP Model of Relapsing–Remitting Multiple Sclerosis

International Journal of Molecular Sciences

Giulia Russo 1,2, Fianne Sips 3, Simona Catozzi 4, Pauline Bambury 4, Annette Janus 5, Mario Torchia 4, Valentina Di Salvatore 1 , Luca Emili 4, Daniel Röshammar 4,*, Francesco Pappalardo 1,2 and Yann Godfrin 5

  1. Department of Drug and Health Sciences, Università degli Studi di Catania, 95125 Catania, Italy; [email protected] (G.R.); [email protected] (V.D.S.); [email protected] (F.P.)
  2. Mimesis Srl, 95125 Catania, Italy
  3. InSilicoTrials Technologies B.V., 5232 AC 's-Hertogenbosch, The Netherlands; [email protected]
  4. InSilicoTrials Technologies Spa, 34123 Trieste, Italy; [email protected] (S.C.);[email protected] (P.B.); [email protected] (M.T.); [email protected] (L.E.)
  5. Axoltis Pharma, 69008 Lyon, France; [email protected] (A.J.); [email protected] (Y.G.)
  6. * Correspondence: [email protected]
Axoltis Pharma published this content on February 02, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2026 at 09:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]